Table 1.

Biodistribution of ¹¹¹In-tilmanocept

Organs	Non-blocked	Blocked
Blood	0.18 ± 0.02	0.2 ± 0.1
Heart	2.2 ± 0.3	1.22 ± 0.05*
Stomach	3.4 ± 0.4	1.7 ± 0.3*
Lung	1.2 ± 0.2	1.1 ± 0.1
Salivary glands	4.4 ± 0.5	1.8 ± 0.2*
Liver	22.6 ± 2.7	14.7 ± 1.3*
Pancreas	3.4 ± 0.2	1.2 ± 0.1*
Spleen	10.4 ± 2.0	6.2 ± 0.3*
Small intestine	1.9 ± 0.8	1.6 ± 0.5
Large intestine	1.3 ± 0.2*	2.5 ± 0.2
Fat	1.02 ± 0.58	0.24 ± 0.03
Skin	1.3 ± 0.2	1.2 ± 0.3
Muscle	0.7 ± 0.2	0.50 ± 0.04
Bone	2.5 ± 0.5	2.2 ± 0.7
Kidney	23.2 ± 5.7*	55.7 ± 4.0
Carcass	14.2 ± 1.7*	22.2 ± 1.1
GI	3.8 ± 1.7	2.9 ± 0.2
Aortaa	0.005 ± 0.000	N/A

Biodistribution of ¹¹¹In-tilmanocept (1.5 pmol/g of body weight) in female C57BL/6 mice, 1 h p.i. Blocked group was co-injected with blocking dose (10 nmol) of non-labelled tilmanocept. Data are presented as the mean percentage of injected dose per gram of tissue (%ID/g ± SD) except in carcass, gastrointestinal tract (GI) and aortas (dissected only from non-blocked mice, n = 2) where the uptakes are presented as %ID per whole sample.

N/A not applicable

*Show significantly lower uptake (p < 0.05)

^aWhole aortas from the sinotubular junction to aortic bifurcation were collected